{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:44:50Z","timestamp":1789454690872,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.leukres.2010.10.027","type":"journal-article","created":{"date-parts":[[2010,12,11]],"date-time":"2010-12-11T09:10:18Z","timestamp":1292058618000},"page":"585-590","source":"Crossref","is-referenced-by-count":34,"title":["Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system"],"prefix":"10.1016","volume":"35","author":[{"given":"Tetsuzo","family":"Tauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsune","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Tsudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Oshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2010.10.027_bib0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-008-0186-0","article-title":"Current and future perspectives on the TARGET system: the registration system for Glivec established by JSH","volume":"88","author":"Kizaki","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.10.027_bib0010","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1200\/JCO.1987.5.6.962","article-title":"Eligibility and extrapolation in cancer clinical trials","volume":"5","author":"Begg","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.10.027_bib0015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.1996.14.4.1364","article-title":"Reducing patient eligibility criteria in cancer clinical trials","volume":"14","author":"George","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.10.027_bib0020","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2003.12.070","article-title":"Clinical trials: time for action","volume":"21","author":"Cassileth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.10.027_bib0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2005.02.6005","article-title":"The importance of reporting patient requirement details in phase III trials","volume":"24","author":"Wright","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.10.027_bib0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.10.027_bib0035","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.10.027_bib0040","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.10.027_bib0045","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.10.027_bib0050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.10.027_bib0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.10.027_bib0060","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2010.10.027_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.187.187","article-title":"Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from multicenter <<Stop Imatinib>>(STIM) study","volume":"112","author":"Mahon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.10.027_bib0070","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.10.027_bib0075","doi-asserted-by":"crossref","first-page":"12233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients recieving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.10.027_bib0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nm0107-15a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Hatifeld","year":"2007","journal-title":"Nat Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610005205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610005205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T15:48:15Z","timestamp":1592149695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610005205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0145212610005205"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.10.027","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}